title: A structural and functional acromegaly classification.
abstract: BACKGROUND
  GH-secreting pituitary adenomas exhibit heterogeneous natural history ranging from small tumors to large aggressive adenomas.
  
  
  OBJECTIVE
  To rigorously classify an acromegaly patient cohort defined by clinical, radiological, histopathological, and outcome characteristics.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Tertiary referral pituitary center.
  
  
  METHODS
  Subjects were selected from a pituitary tumor research registry that includes 1178 patients with pituitary disease. Cluster analysis was performed on 338 acromegaly patients.
  
  
  METHODS
  None.
  
  
  METHODS
  Biochemically active disease with elevated IGF-1 levels at follow-up.
  
  
  RESULTS
  Cluster analysis of all patients yielded 292 who were rigorously classified to three acromegaly types. Type 1 (50%) comprised older patients with the longest follow-up and most favorable outcomes, characterized by densely granulated, nonaggressive microadenomas and macroadenomas. Type 1 tumors extend to the sphenoid sinus more frequently than suprasellar extension (concave tumor image) and express abundant immunoreactive p21 and somatostatin receptor 2. Type 2 (19%) comprised noninvasive, densely or sparsely granulated macroadenomas, without significant extension (flat tumor image), with intermediate biochemical outcome. Type 3 (31%) was characterized by sparsely granulated aggressive macroadenomas and comprised patients with adverse therapeutic outcomes, despite receiving more treatments. These tumors extend to both the sphenoid sinus and suprasellar regions with commonly encountered optic chiasm compression ("peanut" magnetic resonance image), with low tumor p21 and somatostatin receptor 2 expression.
  
  
  CONCLUSIONS
  After validation, this classification may be useful to accurately identify acromegaly patients with distinctive patterns of disease aggressiveness and outcome, as well as to provide an accurate tool for selection criteria in clinical studies.
authors.affiliation: Pituitary Center, Department of Medicine (D.C.-R., J.D.C., O.C., V.S.B., S.M.), Surgery, Pathology and Laboratory Medicine (A.G.), and Neurosurgery (A.N.M.), Cedars-Sinai Medical Center, Los Angeles, California 90048.
authors.forename: Daniel
authors.initials: D
authors.lastname: Cuevas-Ramos
authors.forename: John D
authors.initials: JD
authors.lastname: Carmichael
authors.forename: Odelia
authors.initials: O
authors.lastname: Cooper
authors.forename: Vivien S
authors.initials: VS
authors.lastname: Bonert
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Gertych
authors.forename: Adam N
authors.initials: AN
authors.lastname: Mamelak
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melmed
mesh_terms: D000172:Acromegaly / Q000145:classification* / Q000473:pathology; D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000145:classification* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000145:classification* / Q000378:metabolism / Q000473:pathology
chemical_list: D007334:Insulin-Like Growth Factor I